TICKERNOMICS Sign up
Last Update: 2023-10-04 11:37:19
LogicBio Therapeutics Inc ( LOGC ) https://www.logicbio.com
2.07USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
14.73%
LOGC
2.48%
SPY
36.71%
-64.80%
LOGC
SPY
70.96%
LOGC
0.00%
SPY
262.36%
LOGC
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
68.23
44.72
0.15
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-2.05
6.34
4.34
-511.93
0.00
0.00
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-211.41
100.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
24.2852
-59.92
-70.31
5.92
Other Earnings and Cash Flow Stats:
LogicBio Therapeutics Inc ( LOGC ) Net Income TTM ($MM) is -38.35
LogicBio Therapeutics Inc ( LOGC ) Operating Income TTM ($MM) is -30.94
LogicBio Therapeutics Inc ( LOGC ) Owners' Earnings Annual ($MM) is -36.84
LogicBio Therapeutics Inc ( LOGC ) Current Price to Owners' Earnings ratio is -0.25
LogicBio Therapeutics Inc ( LOGC ) EBITDA TTM ($MM) is -30.10
LogicBio Therapeutics Inc ( LOGC ) EBITDA Margin is 0.00%
Capital Allocation:
LogicBio Therapeutics Inc ( LOGC ) has paid 0.00 dividends per share and bought back 0.0 million shares in the past 12 months
LogicBio Therapeutics Inc ( LOGC ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
LogicBio Therapeutics Inc ( LOGC ) Interest-bearing Debt ($MM) as of last quarter is 7
LogicBio Therapeutics Inc ( LOGC ) Annual Working Capital Investments ($MM) are -2
LogicBio Therapeutics Inc ( LOGC ) Book Value ($MM) as of last quarter is 15
LogicBio Therapeutics Inc ( LOGC ) Debt/Capital as of last quarter is 46%
Other Balance Sheet Stats:
LogicBio Therapeutics Inc ( LOGC ) has 30 million in cash on hand as of last quarter
LogicBio Therapeutics Inc ( LOGC ) has 16 million of liabilities due within 12 months, and long term debt 5 as of last quarter
LogicBio Therapeutics Inc ( LOGC ) has 32 common shares outstanding as of last quarter
LogicBio Therapeutics Inc ( LOGC ) has 33 million USD of preferred stock value
Academic Scores:
LogicBio Therapeutics Inc ( LOGC ) Altman Z-Score is 0.00 as of last quarter
LogicBio Therapeutics Inc ( LOGC ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
LogicBio Therapeutics Inc ( LOGC ) largest shareholder is Renaissance Technologies Corp owning 282877 shares at 0.59 ($MM) value
Jones Cecilia(Chief Financial Officer) Executed Type F Transaction for -2175 shares of LogicBio Therapeutics Inc ( LOGC ) for the amount of $4371.75 on 2022-01-12
8.93% of LogicBio Therapeutics Inc ( LOGC ) is held by insiders, and 48.70% is held by institutions
LogicBio Therapeutics Inc ( LOGC ) went public on 2018-10-19
Other LogicBio Therapeutics Inc ( LOGC ) financial metrics:
FCF:-43.01
Unlevered Free Cash Flow:-16.21
EPS:-1.51
Operating Margin:-211.41
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-316.08
Beta:5.92
Buffet's Owners Earnings:-36.84
Price to Owner's Earnings:-0.25
About LogicBio Therapeutics Inc ( LOGC ) :
LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. As of November 15, 2022, LogicBio Therapeutics, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc..
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.